$NVO (Novo Nordisk) Support & Resistance Levels, AI Price Target & Institutional Flow.
$NVO (Novo Nordisk) live technical levels: 30D Support Floor at $37.53, 20D SMA Pivot at $39.97, and 30D Resistance Ceiling at $42.18 (14D RSI: 61.7 • BULLISH MOMENTUM (61.7)) — plus live dark pool whale flow, bull/bear thesis, and locked 1-month AI price target.
Spot Price: $41.63 | 30-Day Support Floor: $37.53 (9.85% above) | 10-Day EMA: $40.92 | 20-Day SMA Pivot: $39.97 | 30-Day Resistance Ceiling: $42.18 (1.32% below) | 14-Day RSI: 61.7 (BULLISH MOMENTUM (61.7)) | 30-Day Trading Corridor: 12.39% span. Novo Nordisk ($NVO) is currently trading at $41.63—holding above its 20-day simple moving average ($39.97) and 10-day exponential moving average ($40.92) with a 5-day price velocity of +3.27% and 14-day RSI at 61.7 (BULLISH MOMENTUM (61.7)). With a live market capitalization of $184.66B and a trailing P/E multiple of 11.03x, bullish continuation targets a high-volume test of the 30-day resistance ceiling and options Call Wall at $42.18 (1.32% below spot).
$NVO (Novo Nordisk) Live Key Levels, RSI & Valuation Matrix
| $NVO Technical Metric | Live Value | $NVO Fundamental / Regime Metric | Live Status |
|---|---|---|---|
| Live Spot Price (24h Change) | $41.63 (+2.41%) | Market Capitalization | $184.66B |
| 30-Day Mechanical Support Floor (Put Wall) | $37.53 (9.85% cushion) | 52-Week High / Low Range | $35.12 – $64.16 |
| 20-Day Simple Moving Average (20D SMA) | $39.97 | Trailing P/E Ratio & Dividend Yield | 11.03x • Yield: 4.32% |
| 10-Day Exponential Moving Average (10D EMA) | $40.92 | Average Daily Volume (Liquidity) | 16.57M shares |
| 30-Day Resistance Ceiling (Call Wall) | $42.18 (1.32% upside to test) | Next Scheduled Earnings / Catalyst Window | 2027-02-03 |
| 14-Day Relative Strength Index (RSI) | BULLISH MOMENTUM (61.7) | Saku Momentum Pulse & Health Rating | 68/100 Momentum • 74/100 Health |
Should You Buy $NVO Stock Now or Wait?
Novo Nordisk ($NVO) is currently trading at $41.63—holding above its 20-day simple moving average ($39.97) and 10-day exponential moving average ($40.92) with a 5-day price velocity of +3.27% and 14-day RSI at 61.7 (BULLISH MOMENTUM (61.7)). With a live market capitalization of $184.66B and a trailing P/E multiple of 11.03x, bullish continuation targets a high-volume test of the 30-day resistance ceiling and options Call Wall at $42.18 (1.32% below spot).
Primary downside invalidation for $NVO (Novo Nordisk) centers on a failure to clear the $42.18 30-day resistance ceiling followed by a daily close below the 20-day moving average pivot at $39.97. Losing $39.97 on elevated volume opens a mechanical retest of the $37.53 Put Wall support zone inside a 52-week structural corridor of $35.12 to $64.16.
$NVO Support & Resistance, Institutional Flow & Catalysts.
$NVO Support & Resistance
Spot Price: $41.63 | 30-Day Support Floor: $37.53 (9.85% above) | 10-Day EMA: $40.92 | 20-Day SMA Pivot: $39.97 | 30-Day Resistance Ceiling: $42.18 (1.32% below) | 14-Day RSI: 61.7 (BULLISH MOMENTUM (61.7)) | 30-Day Trading Corridor: 12.39% span.
$NVO Institutional & Whale Flow
Institutional order flow for $NVO (averaging 16.57M shares daily volume) is concentrated between the $37.53 Put Wall support zone and $42.18 Call Wall resistance ceiling, with a live Saku Fundamental Health score of 74/100.
$NVO Catalyst Outlook
Next scheduled earnings window for Novo Nordisk ($NVO): 2027-02-03. Latest tracked headline from simplywall.st: "Ascendis Pharma (ASND) Stock Looks Reasonable Following Its 22% Run".
Latest $NVO (Novo Nordisk) Breaking News & Headlines
About Novo Nordisk ($NVO)
Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.
Saku's quantitative engine continuously monitors $NVO's 30-day mechanical support floor ($37.53), 20-day simple moving average ($39.97), and 30-day resistance ceiling ($42.18) alongside off-exchange dark pool block prints and SEC filings.
Hatch Your Own 24/7 AI Co-Pilot to Guard $NVO.
Step inside the 3D Quant Sanctuary and claim Workstation #4 to hatch your personal AI analyst (Momentum, Dip-Buyer, or Value & Catalyst style). Your agent monitors $NVO 24/7 with locked 1-month price targets, hard stop-loss tripwires, 3x/day shift briefings, and live Koi Bridge debates.

What are the live 30-day support and resistance levels for $NVO (Novo Nordisk)?
Spot Price: $41.63 | 30-Day Support Floor: $37.53 (9.85% above) | 10-Day EMA: $40.92 | 20-Day SMA Pivot: $39.97 | 30-Day Resistance Ceiling: $42.18 (1.32% below) | 14-Day RSI: 61.7 (BULLISH MOMENTUM (61.7)) | 30-Day Trading Corridor: 12.39% span. $NVO currently registers a Saku Momentum Pulse score of 68/100 and a Fundamental Health score of 74/100.
Why is $NVO (Novo Nordisk) moving and what is the bull vs. bear thesis?
Bull Thesis: Novo Nordisk ($NVO) is currently trading at $41.63—holding above its 20-day simple moving average ($39.97) and 10-day exponential moving average ($40.92) with a 5-day price velocity of +3.27% and 14-day RSI at 61.7 (BULLISH MOMENTUM (61.7)). With a live market capitalization of $184.66B and a trailing P/E multiple of 11.03x, bullish continuation targets a high-volume test of the 30-day resistance ceiling and options Call Wall at $42.18 (1.32% below spot). Bear Thesis: Primary downside invalidation for $NVO (Novo Nordisk) centers on a failure to clear the $42.18 30-day resistance ceiling followed by a daily close below the 20-day moving average pivot at $39.97. Losing $39.97 on elevated volume opens a mechanical retest of the $37.53 Put Wall support zone inside a 52-week structural corridor of $35.12 to $64.16.
What are $NVO's key fundamentals, 52-week range, and upcoming catalysts?
Novo Nordisk ($NVO) trades with a market cap of $184.66B, a P/E ratio of 11.03x, and a 52-week range of $35.12 to $64.16. Next scheduled earnings window for Novo Nordisk ($NVO): 2027-02-03. Latest tracked headline from simplywall.st: "Ascendis Pharma (ASND) Stock Looks Reasonable Following Its 22% Run".